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Table 1
Minimum inhibitory concentrations (MICs) and percent resistance (%R) of Aggregat-
ibacter actinomycetemcomitans to amoxicillin and amoxicillin/clavulanic acid (AMC)
(n=100 clinical isolates) and to metronidazole (n=41 clinical isolates).
Amoxicillin AMC Metronidazole
Aerobic
growth
Anaerobic
growth
MIC50 (g/mL) 0.5 0.5 10 2.25
MIC90 (g/mL) 1.5 1.0 56 8
MIC range (g/mL) 0.38–2.0 0.25–2.0 0.75–256 0.38–256
%Ra 0 0 b
MIC50/90, MIC required to inhibit 50% and 90% of the isolates, respectively.
a Haemophilus inﬂuenzae was used as the reference species: susceptible
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[2g/mL> resistant according to European Committee on Antimicrobial Suscep-
ibility Testing (EUCAST) clinical breakpoint table v.3.1, valid from 2013-02-11.
b No reference species is available for metronidazole resistance breakpoints.
usceptibility of pathogens is regularly monitored. Signiﬁcant
ifferences between countries in antibiotic susceptibility proﬁles
f periodontal bacteria have been noted in Europe [5] and South
merican countries [4]. In the present study, no -lactamase-
ositive A. actinomycetemcomitans isolates were found and all
trains appeared susceptible to amoxicillin according to the
UCAST breakpoint (≤2g/mL), which contradicts data from
olombia [3].
We also showed that in vitro metronidazole susceptibility is
etermined by growth conditions. In conclusion, although sev-
ral reports show signiﬁcant differences in susceptibility between
moxicillin and AMC, in this study we found no evidence for
-lactamase production in A. actinomycetemcomitans. Second, sus-
eptibility testing of A. actinomycetemcomitans to metronidazole
hould be performed under anaerobic growth conditions.
Funding: No funding sources.
Competing interests: AJvW is co-owner of LabOral Diagnostics
Houten, The Netherlands), a company that provides dental pro-
essionals with diagnostic microbiology. All other authors declared
o competing interests.
Ethical approval: Not required.
cknowledgment
The authors thank Alex Friedrich for suggestions and critical
eading of the manuscript.
eferences
1] van Winkelhoff AJ, Rodenburg JP, Goené RJ, Abbas F, Winkel EG, de Graaff
J. Metronidazole plus amoxycillin in the treatment of Actinobacillus actino-
mycetemcomitans associated periodontitis. J Clin Periodontol 1989;16:128–31.
2] Pavicic´ MJAMP, van Winkelhoff AJ, Pavicic´-Temming YAM, de Graaff J. Met-
ronidazole susceptibility factors in Actinobacillus actinomycetemcomitans. J
Antimicrob Chemother 1995;35:263–9.
3] Ardila CM, Granada MI, Guzmán IC. Antibiotic resistance of subgingival species
in chronic periodontitis patients. J Periodontal Res 2010;45:557–63.
4] Veloo ACM, Seme K, Raangs E, Rurenga P, Singadji Z, Wekema-Mulder G, et al.
Antibiotic susceptibility proﬁles of oral pathogens. Int J Antimicrob Agents
2012;40:450–4.
5] van Winkelhoff AJ, Herrera D, Oteo A, Sanz M. Antimicrobial proﬁles of peri-
odontal pathogens isolated from periodontitis patients in The Netherlands and
Spain. J Clin Periodontol 2005;32:893–8.
A.J. van Winkelhoff a,b,∗
a Department of Medical Microbiology, University Medical CenterGroningen, University of Groningen, Hanzeplein 1, 9713 GZ
Groningen, The Netherlands
b Center for Dentistry and Oral Hygiene, University Medical Center
Groningen, University of Groningen, Antonius Deusinglaan 1, 9713
AV Groningen, The Netherlandsntimicrobial Agents 43 (2014) 474–483
P. Rurenga
Z. Singadji
G. Wekema-Mulder
Department of Medical Microbiology, University Medical Center
Groningen, University of Groningen, Hanzeplein 1, 9713 GZ
Groningen, The Netherlands
∗ Corresponding author. Present address: Center for Dentistry and
Oral Hygiene, Antonius Deusinglaan 1, 9713 AV Groningen, The
Netherlands. Tel.: +31 50 363 2995; fax: +31 50 363 2696.
E-mail address: a.j.van.winkelhoff@umcg.nl (A.J. van Winkelhoff)
18 December 2013
http://dx.doi.org/10.1016/j.ijantimicag.2014.01.024
In vitro activities of tetracyclines against differ-
ent clones of multidrug-resistant Acinetobacter
baumannii isolates from two Iranian hospitals
Sir,
Acinetobacter baumannii has emerged as one of the most
challenging healthcare-related pathogens and its occurrence has
increased worldwide, especially in patients admitted to intensive
care units [1]. A. baumannii isolates are frequently resistant to mul-
tiple antimicrobial agents and there are recent reports of isolates
resistant to virtually all clinically relevant drugs [1].
Minocycline and tigecycline are both available for intravenous
infusion and have been approved by the US Food and Drug
Administration (FDA) for use in A. baumannii infections [2]. These
two antibiotics have been shown to maintain encouraging activi-
ties against multidrug-resistant A. baumannii (MDR-AB) [2,3]. The
Tigecycline Evaluation and Surveillance Trial TEST data reported
minocycline and tigecycline as the most active agents by suscep-
tibility rate and MIC90 value (minimum inhibitory concentration
required to inhibit 90% of the isolates), respectively, against 483
carbapenem-resistant A. baumannii isolates [3].
In the present study, the in vitro activities of tigecycline,
minocycline and doxycycline against 67 MDR-AB isolates recov-
ered from 29 burn and 38 non-burn Iranian patients hospitalised
in Tehran and Tabriz, respectively, were studied. MICs of tetra-
cyclines, imipenem, meropenem, amikacin and gentamicin were
determined by Etest (AB BIODISK, Solna, Sweden). The distribu-
tion and prevalence of the most relevant acquired resistance genes
were assessed. Molecular epidemiological relationships were also
investigated using DiversiLab repetitive sequence-based PCR (rep-
PCR), multilocus sequence typing (MLST) and sequence group (SG)
determination.
Amongst the 67 MDR-AB isolates, the prevalence rate of non-
susceptibility to each antibiotic was >70%, with the exception of
doxycycline (n=30; 44.8%), tigecycline (n=24; 35.8%) and minocy-
cline (n=7; 10.4%). The MIC50 and MIC90 values of tigecycline,
minocycline and doxycycline, respectively, were as follows: 3 and
6mg/L; 1 and 24mg/L; and 8 and >256mg/L. The MIC50 and MIC90
values of tigecycline in burn isolates were higher than those of
non-burn isolates (3 and 6mg/L vs. 2 and 4mg/L, respectively).
All isolates were positive for adeB showing amplicons of the
expected size (ca. 1 kb). The most common acquired resistance
gene was aph(3′)-VIa, which was found in 64 isolates (95.5%), fol-
lowedbyblaOXA-23-like in 47 isolates (70.1%),ant(2′′)-Ia in 38 isolates
(56.7%), blaOXA-40-like in 24 isolates (35.8%), aac(3′)-Ia in 22 isolates
(32.8%), aph(3′)-Ia/ant(3′′)-Ia in 13 isolates (19.4%), tetB in 13 iso-
lates (19.4%), aac(6′)-Ib in 11 isolates (16.4%) and armA in 6 isolates
(9.0%). Thirteen tetB-carrying isolates, including seven non-burn
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Table 1
Epidemiological, phenotypic and genotypic characteristics of 67 multidrug-resistant Acinetobacter baumannii isolates from Iran.
rep-PCR SG B/NB Resistance genes
OXA-23 OXA-40 armA aac(3′)-Ia aac(6′)-Ib aph(3′)-Ia aph(3′)-VIa ant(2′′)-Ia ant(3′′)-Ia tetB
A 1 0/6 1 0 1 5 1 1 5 3 2 1
A – 0/2 0 0 0 1 0 0 2 1 0 0
B 1 1/2 3 1 0 3 1 0 3 1 0 0
C – 2/0 0 2 0 0 0 2 2 2 0 0
D – 6/0 0 6 1 0 0 1 6 2 1 0
E 3 7/0 4 3 0 1 1 1 7 7 1 0
E – 2/0 0 2 0 0 1 0 2 2 0 0
F 2 7/0 7 7 0 1 2 1 6 6 1 0
G – 2/0 2 0 0 0 0 0 2 0 0 0
H – 2/2 4 0 0 0 1 0 4 4 2 3
I 1 3/8 11 1 2 6 2 3 10 1 1 2
J 1 1/5 6 0 1 4 0 2 6 2 1 1
Si 1,2 1 0/2 2 0 0 1 0 1 2 1 1 2
Si 3 – 1/0 1 0 1 0 0 0 1 1 0 0
Si 4 2 1/0 1 1 0 0 1 0 1 1 0 0
Si 5,8 – 1/1 2 0 0 0 1 1 2 2 2 2
Si 6 2 0/1 1 0 0 0 0 0 1 1 1 1
Si 7 – 1/0 1 0 0 0 0 0 1 1 0 1
Si 9 1 1/0 1 1 0 0 0 0 1 0 0 0
rep-PCR SG B/NB MIC range (mg/L)
IPM MEM AMK GEN TIG MIN DOX
A 1 0/6 1.5–32 2–32 12–256 16–256 0.75–3 0.38–4 2–256
A – 0/2 1.5–3 1.5–3 12–16 12–256 3 0.38 2–3
B 1 1/2 32 32 32–256 12–96 0.25–1.5 0.09–0.25 0.5–1
C – 2/0 32 32 128–192 24–256 0.19–0.38 0.03 0.19–0.25
D – 6/0 32 32 96–256 6–256 0.75–3 0.03–0.12 0.12–0.25
E 3 7/0 32 32 32–256 256 0.38–6 0.19–1 12–256
E – 2/0 32 32 256 256 0.5–4 0.5–3 256
F 2 7/0 32 32 12–256 256 2–6 0.38–1 2–6
G – 2/0 32 32 128–256 256 1–1.5 0.38 1–4
H – 2/2 32 32 32–256 24–256 0.5–1.5 0.38–6 2–256
I 1 3/8 32 32 12–256 16–256 1.5–4 0.38–6 2–256
J 1 1/5 32 32 8–256 12–256 1–4 0.06–12 0.25–256
Si 1,2 1 0/2 32 32 48–256 48–256 2–4 12–24 256
Si 3 – 1/0 32 32 256 256 0.75 0.19 6
Si 4 2 1/0 32 32 64 256 3 0.25 2
Si 5,8 – 1/1 32 32 16–32 256 0.5–1.5 3–4 256
Si 6 2 0/1 32 32 96 256 3 6 256
Si 7 – 1/0 32 32 64 256 1 3 256
Si 9 1 1/0 32 32 256 48 0.5 0.02 0.19
rep-PCR, repetitive sequence-based PCR (DiversiLab); SG, sequence group; B, burn isolates; NB, non-burn isolates; IPM, imipenem; MEM, meropenem; AMK, amikacin; GEN,
gentamicin; TIG, tigecycline; MIN, minocycline; DOX, doxycycline; Si, singleton; MIC, minimum inhibitory concentration.
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tnd six burn isolates, were resistant to tetracycline and showed
inocycline MICs ranging from 2mg/L to 24mg/L and doxycycline
ICs >256mg/L.
A total of 10 DiversiLab rep-PCR subtype clusters including two
r more isolates were deﬁned (herein named A–J), whereas nine
solates were classiﬁed as singletons (Table 1). Ten sequence types
STs), including ST2, ST25, ST85, ST94, ST136, ST307 and four novel
equence types (ST323, ST324, ST325 and ST328), were detected.
ultiplex PCR attributed 29, 9 and 7 isolates, respectively, to Euro-
ean Clones (ECs) II, I and III (SGs 1, 2 and 3).
Resistance to tigecycline was observed most frequently in iso-
atesbelonging toSG2andSG1,witheightandsix resistant isolates,
espectively.Moreover, isolates attributed toSG1showed thehigh-
st prevalence of resistance to minocycline and doxycycline, with
and 13 resistant isolates, respectively. As summarised in Table 1,
he resistance determinantsweremost frequently observed among
solates belonging to SG 1.In this study, most of the MDR-AB isolates (87%) were classiﬁed
s tetracycline-resistant. In contrast, except for one isolate, the
etracycline-resistant isolates were found to be susceptible orintermediately susceptible to minocycline. Tigecycline was also
active with 64% of isolates displaying a MIC≤2mg/L. This preva-
lence is slightly lower than the rate recently reported in a survey in
Iran where ca. 80% of the isolates proved to be susceptible [4]. This
could be due to a higher prevalence of non-susceptible isolates in
burn patients in whom tigecycline is being used for A. baumannii
infections.
The SG 1/EC II isolates showed the most heterogeneous
pattern of genetic determinants and the highest resistance
rates to tigecycline, minocycline and doxycycline. Clonality of
non-susceptible isolates was further investigated using rep-
PCR. Although minocycline-non-susceptible isolates were equally
distributed between clusters and singletons, tigecycline-non-
susceptible isolates mainly clustered into rep-PCR subtypes E and
F, the two prominent clusters in burn isolates. This ﬁnding agrees
with previous reports and supports the view that multiple MDR-
AB epidemic strains can be selected by antibacterial use pressure
in healthcare settings [5].
This study conﬁrms the major role of the highly successful ECs
I and II in the spread of MDR-AB strains in Iran. Striking genetic
4 al of A
v
a
s
t
t
F
C
E
A
P
i
r
R
[
[
[
[
[
h78 Letters to the Editor / International Journ
ersatility may allow EC II strains to develop resistance to nearly
ll clinically relevant agents. Tigecycline and minocycline may be
till considered effective therapeutic options for MDR-AB infec-
ions. However, ongoing monitoring of A. baumannii susceptibility
o these antibiotics is required.
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A novel GyrB mutation in meticillin-resistant
Staphylococcus aureus (MRSA) confers a
high level of resistance to third-generation
quinolones
Sir,
Fluoroquinolones are widely used to treat respiratory and
urinary tract infections. The development of ﬁrst-generation
quinolones began with nalidixic acid, and the new quinolone (ﬂu-
oroquinolone) antimicrobial agents were developed [1].
Second-generation quinolones, such as ciproﬂoxacin, nadi-
ﬂoxacin, sparﬂoxacin and levoﬂoxacin, unequally inhibit topo-
isomerase IV and DNA gyrase, and the primary target enzymes
differ with each drug type [2]. The third-generation quinolones,
such as pazuﬂoxacin, moxiﬂoxacin and sitaﬂoxacin, have strong
antimicrobial activity, especially against Gram-positive bacteria
such as Streptococcus pneumoniae, because they target both topo-
isomerase IV and DNA gyrase [3]. Treatment with systemic-acting
ﬂuoroquinolones induces resistance in meticillin-resistant Staphy-
lococcus aureus (MRSA), which are generally off-target bacteria [4].
High-levelﬂuoroquinolone-resistantS. aureusemerge throughpro-
cessive mutations in the quinolone resistance-determining region
(QRDR) of GrlA and GyrA. To investigate the mechanism of high-
level resistance to third-generation quinolones, the amino acid
mutations present in GrlA, GrlB, GyrA and GyrB were analysed.
A total of 189 MRSA isolates were collected from ﬁve Japanese
hospitals between 1999 and 2005. All strains were isolated from
non-respiratory departments. The minimum inhibitory concentra-
tion (MIC)wasdeterminedusing theagardoublingdilutionmethod
according to Clinical and Laboratory Standards Institute (CLSI)
guidelines. Pazuﬂoxacin (Toyama Chemical Co., Ltd., Tokyo, Japan),
moxiﬂoxacin (Bayer Yakuhin, Ltd., Osaka, Japan) and sitaﬂoxacin
(Daiichi Sankyo Co., Ltd., Tokyo, Japan) were kindly provided by
their manufacturers. Ciproﬂoxacin, sparﬂoxacin and levoﬂoxacin
were purchased from Wako Pure Chemical Industries Ltd. (Osaka,
Japan). The amino acid sequences ofGrlA, GrlB, GyrA andGyrBwere
determinedby sequencing the relevant genes.Nadiﬂoxacin (Otsuka
Pharmaceutical Co., Ltd., Tokyo, Japan) was used to select for muta-
tions in GyrA and/or GyrB because it primarily targets and binds
to DNA gyrase. Mutant strains were constructed by the following
method. Strains were grown for 16h in tryptone soya broth (Oxoid
Ltd., Basingstoke, UK). Cells (ca. 1010 CFU) were then spread on
tryptone soya agar (Oxoid Ltd.) containing 128g/mL nadiﬂoxacin.
Strains that grew on the selective medium were considered high-
level third-generation quinolone-resistant mutants.
Approximately one-third of the strains (34.4%) were
moxiﬂoxacin-resistant (MIC>2g/mL). High-level moxiﬂoxacin
resistance (MIC≥128g/mL) was found in 10 strains (5.3%).
These data show that ﬂuoroquinolone-resistant MRSA are
disseminated on the non-targeting sites of third-generation
quinolones. On the other hand, no high-level sitaﬂoxacin-resistant
strain (MIC≥128g/mL) was found in the present study.
When the amino acid sequences of GrlA, GrlB, GyrA and GyrB
were determined, two high-level moxiﬂoxacin-resistant strains
carrying themutations S80Y+E84K inGrlA andS84L+E88R inGyrA
were found (group D) (Table 1). This is the ﬁrst time the E88R
mutation in GyrA has been observed in S. aureus. Despite identi-
cal mutation locations, the MICs of pazuﬂoxacin, moxiﬂoxacin and
sitaﬂoxacin for the mutant group D strains were two- to fourfold
higher than those of themutant group C strains. Furthermore, eight
high-level moxiﬂoxacin-resistant strains carrying the mutations
S80Y+E84K in GrlA, S84L+E88G in GyrA and E477D in GyrB were
found (group E). The mutation E477D in GyrB is a novel amino acid
substitution for S. aureus. TheMICs ofmoxiﬂoxacin and sitaﬂoxacin
for mutant group E were higher than those for mutant group C. The
